Posted by AGORACOM
at 8:29 AM on Thursday, March 18th, 2021
Engaged to conduct and continue previous baseline studies at the Cañariaco Project
9B lbs copper, 2M oz gold and 54M oz silver in: Measured and Indicated Resources
Candente Copper Corp. (TSX: DNT, BVL: DNT) (“Candente Copper”, “the Company”) is pleased to announce that Yaku Consultores (“Yaku”) has been engaged to conduct and continue previous baseline studies at the Cañariaco Project located in Northern Peru. The work will be part of environmental impact studies and habitat protection for all exploration phases of permitting including drilling and also for the community and regional stakeholders.
“We are excited to be moving the Cañariaco project forward with Yaku’s environmental work and new engineering studies underway by Ausenco. Timing couldn’t be better as Cañariaco has been identified by both Goldman Sachs and Deutche Bank as one of the top copper projects needed to supply the upcoming supply-demand shortage for copper,” says Joanne Freeze, President and CEO, Candente Copper.
Yaku is comprised of a team of highly experienced professionals focused on providing quality environmental and social consulting services. These services contribute to the sustainable development of the environment and exceed regulations.
Candente Copper has recently obtained the respective authorizations from SERFOR and PRODUCE (Peruvian authorities for National Forest and Wildlife Services and the Ministry of Production) to conduct new monitoring of Water Quality, Air Quality, Noise Levels and Biology, Wild Flora and Fauna and Hydrobiology. Yaku has begun collecting new data within the project area which will add significantly to the studies that Candente Copper has been conducting such since 2004.
Given the difficult situation for the community with the COVID-19 epidemic, the company is also collaborating with local health facilities to assist in the protection and care of citizens in the area surrounding Cañariaco. To date, the Company has assisted with PPE supplies and the operation of emergency health equipment.
About Candente Copper
Candente Copper is a mineral exploration company engaged in the acquisition, exploration, and development of mineral properties. The Company is currently focused on its 100% owned Cañariaco project, which includes the Feasibility stage Cañariaco Norte deposit as well as the Cañariaco Sur deposit and Quebrada Verde prospect, located within the western Cordillera of the Peruvian Andes in the Department of Lambayeque in Northern Peru.
Please see https://www.candentecopper.com/investors/presentations for details from previous resource and engineering studies which delineated 9B lbs copper, 2M oz gold and 54M oz silver in: Measured and Indicated Resources of 752.4 million tonnes grading 0.45% copper, 0.07 grams per tonne (“g/t”) gold and 1.9 g/t silver (0.52% Cu equivalent) containing 7.533 B lb Cu, 1.67 M oz Au and 45.24 M oz Ag and Inferred Resources of 157.7 million tonnes grading 0.44% copper, 0.06 g/t gold and 1.8 g/t silver containing 1.434 B lb Cu, 0.3M oz Au and 8.932 M oz Ag.
Posted by AGORACOM
at 2:46 PM on Wednesday, March 17th, 2021
CLIENT FEATURE: Hollister Biosciences Inc. (HOLL: CSE) – Acquiring, developing and powering class-leading cannabis consumer products.
WHY HOLLISTER?
Vertically integrated, high-margin cannabis company with high-quality cannabis and hemp products in over 280 dispensaries throughout California and over 90 dispensaries throughout Arizona, plus joint ventures, licensing agreements, and partnerships with global brands.
Hollister controls the whole process from manufacturing to sales, to distribution. From seed to shelf.
Fully licensed and compliant and have established a statewide distribution within California for medical and recreational cannabis.
The U.S. market for cannabis-infused drinks is expected to grow to $1.4 billion by 2024. Zenith Global.
The market for hemp-derived CBD products was USD $591 Million in 2018, expected to reach USD $22 Billion by 2022.
Recent Highlights:
Q4 2020 Financial Highlights:
Q4 2020 Performance Includes CDN $14.93 Million in Revenue With an Estimated CDN $2.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019
Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labelling manufacturing. Products are sold in 370 dispensaries across Arizona and California.
Hollister Biosciences owns 100% of Venom Extracts, a category-leading brand that sold over 4 million grams in 2020, accounting for up to 30 percent of category sales in Arizona.
Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.
The wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
What Brands Does Hollister Own?
Hollister $HOLL.ca $HSTRF
$CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca
Hollister Biosciences Inc. is traded on the CSE as HOLL.
Posted by AGORACOM
at 10:13 AM on Wednesday, March 17th, 2021
Medical-grade protective gear designed and made in Canada ;
Offers greater certainty regarding source, quality and timely delivery of genuine N95 masks.
VANCOUVER, BC , March 17, 2021 /CNW/ – Maitri Health Technologies Corp. (“Maitri”) (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the availability of N95 medical-grade protective masks, one of the few, domestically manufactured N95 masks to receive Health Canada certification.
N95 masks are among the most in-demand and difficult to source pieces of personal protective equipment (PPE) commonly used by hospital, healthcare and other frontline workers. N95 masks filter out at least 95 per cent of very small particles, including airborne droplets.
Maitri’s N95 masks, manufactured in Port Coquitlam, B.C. through an exclusive partnership with INNO Lifecare, were approved by Health Canada in March.
“Maitri is delivering what governments and organizations across Canada have sorely needed and requested since the beginning of the pandemic – a domestically manufactured and certified N95 mask,” said Andrew Morton, CEO of Maitri.
Posted by AGORACOM
at 9:46 AM on Wednesday, March 17th, 2021
The partnership will launch prediction games for major live esports events
“The partnership with TGS Esports brings forth a new platform that will enable us to capture new opportunities within the fast-growing esports market,” said Scott Burton, CEO of FansUnite.
VANCOUVER, BC, March 17, 2021 /CNW/ – TGS Esports Inc. (“TGS” or the “Company”) (TSXV: TGS) (FRA: 5RH)) is pleased to announce that it has entered into a strategic partnership with FansUnite Entertainment Inc. (CSE: FANS) (OTCQB: FUNFF) (“FansUnite”), to launch live esports tournaments prediction games.
TGS All New Prediction Game (CNW Group/TGS Esports Inc)
TGS partners with organizations and brands to build and grow their esports communities via tournaments, broadcast production and events. Through the partnership, FansUnite will incorporate its technology solutions into TGS events to establish a new prediction platform where live audience predictions can be placed on multiple outcomes within every white-label esports event run by TGS. Viewers can make live predictions during TGS events for which they can win prizes if their selections are correct.
Esports revenue in 2020 was over $1 billion[1], excluding revenues from betting. TGS has built white-label esports experiences for over 15 brands, interacting with over 200,000 gamers and by offering prediction games, TGS is able to increase the level of engagement between fans and brands.
Additionally, the prediction games from the platform will be featured on TGS’ Pepper Esports platform which will enable all tournament organizers to offer predictions and rivalry challenges in their tournaments to their viewers.
“Live predictions is a feature our brand partners have been asking us to implement for a long time.” said Spiro Khouri, CEO of TGS Esports Inc. “By implementing FansUnite’s technology into our esports events TGS is able to increase the level of engagement between fans and brands.”
“The partnership with TGS Esports brings forth a new platform that will enable us to capture new opportunities within the fast-growing esports market,” said Scott Burton, CEO of FansUnite. “TGS collaborates with numerous esports event organizers who have a large following of enthusiastic esports gamers who like to participate in their events. Our online betting solutions coupled with TGS esports platform will enable us to attract a new and widening audience from these events.”
Binovi is well-positioned to further commercialize and capitalize on the massive demand for Vision Therapy and Training For Athletes and Education.
Strong IP Portfolio
1 in 4 people on the planet have vision problems that go beyond simply not being able to read those letters on the wall and requiring a prescription.
Since the launch of Binovi, more than 800 organizations have been registered and have used the platform for vision therapy, sports vision performance.
Clients Include:
Dallas Stars (NHL)
Chicago Cubs (MLB)
Sporting KC (MLS)
Tennis Canada
Showcased During NFL Scouting Combine
Company’s Vision Therapy Products Used In:
Over 1,500 Practices
20 Countries
These organizations have created nearly 31,000 users and have completeded more than 400,000 active sessions centred around the Binovi Library list of activities, custom activities created by member organizations.
Flagship “Binovi” Is State-Of-The-Art Platform
Measures 14 Key Vision Skills
Essential For Maximizing Brain Performance
Signed Sports Vision Partnership With Eli Wilson Goaltending
World Leader In Goaltending Development
600 Active Goaltending Camp Participants
50,000 Global Aspiring Goaltenders
Announced a strategic partnership with STEM Sports
Expanded its global reseller network with a partnership with Sport-Orthèse, major European sports e-seller
Sports Performance Market is a $600 Billion Opportunity
Vision Therapy captures 3% of a $36B Yearly Vision Market today.
Vision Therapy grew by 22% in 2020 and won 4% of the $39B Yearly Market in 2020 with organic growth.
VISN’s sights are set on disrupting the sports performance industry in 2021, as we receive engagement from leaders within the human performance – sports performance industry.
The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014, and is expected to grow at a CAGR of 5.9% to nearly $614.1B by 2021.
What is VISN?
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance.
Binovi is designed for vision optimization and the enhancement of cognitive skills related to human performance.
Binovi Technologies Corp (TSX-V: VISN | OTCQB: BNVIF) is reshaping V Education, Vision Care, and Performance through Purposeful, Powerful Vision Training
Utilizing in-office and home-based activity protocols, the innovative Binovi platform helps optometric practices gain greater results, faster, with improved patient satisfaction in areas ranging from sports performance to binocular vision abnormalities.
In a world in which competitors are seeking an edge, Binovi vision training develops faster brains to deliver that edge.
How Does VISN Work?
Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training.
Binovi goes far beyond fixing eyes that simply can’t see a bunch of letters on an eye chart. Rather, Binovi delivers higher-performing brains by optimizing the performance of the eyes. Binovi synchronizes your eyes and your brain to deliver maximum performance for athletes and students.
Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort.
Who Uses VISN?
Binovi is currently used in over 20 countries and supported by recognized optometry leaders.
Patients: Optometrist-lead vision therapy for patients suffering from developmental issues or recovering from injury.
Optometry Professionals: Practicing optometrists and vision therapists working in development, rehabilitation, and healthy ageing.
Athletes: Optometry-backed tools to help improve sports vision performance indicators like reaction time and hand-eye coordination.
Binovi $VISN.ca $BNVIF
$EYPT $KALA $PTON $WELL.ca $DOC.ca $DOCRF
Binovi Techologies Corp. is traded on the TSX.V as VISN.
Posted by AGORACOM
at 11:02 AM on Tuesday, March 16th, 2021
*Tournaments break participation and viewership records for the company *Top channel in Twitch’s popular RocketLegue category
VANCOUVER, BC, March 16, 2021 /CNW/ – TGS Esports Inc. (“TGS” or the “Company”) (TSXV: TGS) (FRA: 5RH) is pleased to announce two record-shattering weekends of white label events.
Over the weekend of March 5-7th, TGS ran four events for its partner brands, including Telcel and NorQuest College. These events had 1400+ players participating and attracted 35,000+ viewers on their TGS produced live streams, setting new participation and viewership records for the company.
The following weekend, March 12-14th, TGS ran two more events for its partner brands that attracted 96,000+ viewers, which was another new and significant participation and viewership record for TGS. Both of these streams featured the popular game title Rocket League, and both streams led Twitch’s Rocket League viewership category throughout the day.
“Brands spent over $500 million on esports events & sponsorship in 20201 and they are looking to spend their money where it has the greatest impact,” said Spiro Khouri, CEO of TGS. “We make it an easy decision for brands to spend their money with TGS.”
Posted by AGORACOM
at 10:36 AM on Tuesday, March 16th, 2021
TORONTO , March 16, 2021 /PRNewswire/ – Predictiv AI Inc. (TSXV: PAI) (OTC: INOTF) (FSE: 71TA) (” Predictiv AI ” or the ” Company “), a software and solutions provider in the artificial intelligence markets is pleased to announce its dynamic new partnership with the Waterloo Artificial Intelligence Institute (“Waterloo.AI”) at the University of Waterloo . This partnership will allow Predictiv AI’s subsidiary, AI Labs Inc. (“AI Labs”), to pursue its various innovations through leveraging Waterloo.AI as an extension of the Predictiv AI team.
The collaboration will allow access to the world’s top artificial intelligence resources, creating much greater bandwidth in ideation, research, and development of solutions for real-world problems. Predictiv AI also looks forward to participating in and supporting Waterloo.AI events and introducing other synergistic partners to the program. Beyond having access to an unparalleled talent pool of academics and their teams for research and development, the partnership also provides for round table participation amongst Waterloo.AI partners.
“We are thrilled to have Predictiv AI join as a partner with Waterloo,” said Harold Godwin , Managing Director of Waterloo.AI. “This is a very exciting time for our university and Waterloo.AI, and we are grateful for the interest and ongoing support of our partners, including our newest, Predictiv AI.”
“We are very excited and honoured to be working with one of the world’s leading artificial intelligence institutions. We will now be able to accelerate our innovations and scale our team’s productivity while learning new ways to approach projects with new and unique technologies,” said Michael Lende, CEO of Predictiv AI.
Posted by AGORACOM
at 10:31 AM on Tuesday, March 16th, 2021
Mountain Valley MD Holdings Inc.(the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials under the supervision of The People’s Republic of Bangladesh’s Ministry of Fisheries & Livestock for the Company’s injectable solubilized Ivermectin technology, Ivectosol™ 1%.
“We are very excited to be welcoming Mountain Valley MD to The People’s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product,” stated Bangladesh’s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.
MVMD is working with its local partner R&G Group inside Bangladesh to quickly advance its research and development, and manufacturing capabilities inside the country.
MVMD’s Ivectosol™ 1%, a fully solubilized form of the anti-parasitic drug Ivermectin, will be tested in cattle, goat and poultry under the supervision of the Bangladesh Government’s approved and authorized laboratories and research institutes. The tests will be conducted by way of intra-muscular needleless injection of Ivectosol™ 1% in an effort to demonstrate superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with advanced drug withdrawal time control, versus current commercially available forms.
The trials are scheduled to commence in early April, 2021 and are anticipated to take 30 days. The trial results are scheduled to be reviewed and approved by the Ministry of Fisheries & Livestock and Ministry of Health and will enable the Company to advance against immediate commercialization opportunities. The Company is finalizing production supply agreements with key Bangladesh pharmaceutical partners to produce its Ivectosol™ 1% for use and distribution throughout Bangladesh and as a production hub for broader global distribution. The production scheduling and pricing are currently being finalized under non-disclosure agreement (“NDA”), including securing the sufficient Ivermectin Active Pharmaceutical Ingredient (“API”) quantity for anticipated global demand.
“We’ve been extremely impressed by the speed and pace with which the Government of the People’s Republic of Bangladesh continues to provide our teams with incredible support for the testing and preparedness of an accelerated commercialization pathway for Ivectosol™ 1%,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “Our pharmaceutical partners are both FDA and EU compliant and support our broader objectives to scale for global production. Securing top quality manufacturing within a competitive cost structure is critical to align with one of the core tenets of MVMD’s mission to ensure accessibility to our technology for even the most disadvantaged nations.”
Posted by AGORACOM
at 9:56 AM on Tuesday, March 16th, 2021
Victory Square received 4,411,765 common shares of Cloud Nine Web3 Technologies Inc. (CSE: CNI) at a deemed issue price of $1.36 per common share for a purchase price of $6,000,000
The share price of Cloud Nine (CSE: CNI) closed on March 15, 2021 at $1.79 per common share, valuing Victory Square’s 4,411,765 common shares at $7,897,059.35
Victory Square will have the right to dividend up to 15% of the total number of the Consideration Shares issuable hereunder to its shareholders
Company exercised 350,000 warrants in Argo Blockchain PLC (LON: ARB) for an approximate $1,488,000 gain (as at March 15th, 2021)
VANCOUVER, British Columbia, March 16, 2021 — Victory Square Technologies Inc. (“Victory Square” or the “Company“) (CSE:VST) (OTC:VSQTF) (FWB:6F6) — is pleased to announce that it has signed and closed an asset purchase agreement dated March 15, 2021 to sell certain intellectual property assets related to a development stage VPN platform (the “Acquisition”) to Cloud Nine Web3 Technologies Inc. (“Cloud Nine” )(CSE: CNI).
“We’ve spent the last 6 years connecting with and investing in some of the brightest and disruptive minds in the Technology space; quietly building up a stockpile of applications and IP while waiting for an inflection point to start unleashing these applications to market,” said Victory Square CEO Shafin Diamond Tejani.
“This 6 million sale of IP and the $1.5 million gain on Argo points to the extensive depth of the Victory Square portfolio and our ability to monetize and provide value to our shareholders.”
In consideration for the Acquisition, Victory Square received 4,411,765 common shares of Cloud Nine at a deemed issue price of $1.36 per common share for a sale price of $6,000,000.
Posted by AGORACOM
at 8:46 AM on Tuesday, March 16th, 2021
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“) an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, announces it has completed the sale and import (the “Transaction“) of the Company’s high-grade consumer packaged goods (“iMicrodose Packs“) from the Netherlands to Canada under a Health Canada psilocybin import permit obtained by CCrest Laboratories Inc. in partnership with Shaman Pharma Corp.
The Transaction between Red Light Holland and the Montreal, Quebec-based cGMP lab, CCrest Laboratories, is the first of a multi-phase project to expand into the mental wellness pharmaceutical sector by demonstrating a legally compliant route for supplying raw materials containing psychoactive molecules, produced abroad by Red Light Holland, and imported into Canada.
“Today is another ground-breaking, precedent setting and defining leap forward for the entire Psychedelic sector as Red Light Holland has successfully expanded the reach of iMicrodose packs across international borders. As interest in novel psychedelic therapies increase on a daily basis, we will continue to aim to take our natural-occurring packaged psilocybin products to global markets, allowing Red Light Holland to increase our distribution and sales channels. The agreement with Shaman Pharma to utilize its partnership with CCrest Laboratories is part of Red Light Holland’s growth strategy, complementing the international groundwork which we established in the Netherlands, as one of the only legal sources for producing natural raw materials containing psilocybin,” said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland. “The collaboration with Shaman Pharma, who have successfully received our iMicrodose packs on Canadian soil, simply put, is a significant day for the Company and its shareholders. We are very proud to have our Netherlands grown Magic Truffles designed for responsible use via education and information, in Canada. They’ve arrived home and Red Light Holland continues to trailblaze across the world.”
The Transaction is performed with the intent of exploring continued collaboration beyond successfully completing the shipment of Red Light Holland’s consumer packaged goods under a Health Canada import permit. The multi-phase scientific undertaking by CCrest Laboratories is planned to perform each phase of developing viable ingredients to address the demanding requirements of clinical trials, patient’s Special Access Programs, and the downstream supply of production-ready substances.
“We are delighted to build a relationship with Red Light Holland as we access the global industry for the very best of both product supply and, with recognition of their position as a market leader in establishing a supply chain from Europe to North America, the ability to meet the exacting needs of a globalized medical marketplace,” stated Alex Grenier, Chief Executive Officer of Shaman Pharma and President of CCrest Laboratories. “Today, we succeeded in demonstrating our strong ability to navigate the stringent regulatory landscape for conducting international transactions of controlled substances and setting the bar for scientific excellence. Furthermore, through this collaboration with Red Light Holland, we were pleased to find that Mr. Shapiro’s vision and ethic is well aligned with compatible long-term objectives for pioneering the psychedelic therapy sector in a manner that exceeds the most complex compliance requirements.”
